| Drug Name: | Candesartan (139481-59-7) |
|---|---|
| PubChem ID: | 2541 |
| SMILES: | CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O |
| InchiKey: | HTQMVQVXFRQIKW-UHFFFAOYSA-N |
| Therapeutic Category: | Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, Cardiovascular Agents |
| Molecular Weight (dalton) | : | 440.463 |
| LogP | : | 4.0286 |
| Ring Count | : | 5 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 118.81 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Spironolactone (52-01-7) | Hyperkalaemia | Antagonistic | Candesartan reduces the levels of aldosterone, which results in the retention of potassium | Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category